Entrepreneur Duke Rohlen has sold four medical-device startups, each time providing quick returns to investors and defying the longer payoff periods that have saddled other venture-capital bets in the industry.
Bardy Diagnostics, a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has recognized the Carnation Ambulatory Monitor (CAM™) with the "Best New Diagnostic Technology" award in the 2019 MedTech Breakthrough Awards program. Bardy Diagnostics earned the distinction for its innovative P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection technology.
HealthQuest Capital, River Cities Capital Funds, Aperture Venture Partners, Aphelion Capital and others invested $35.M into BardyDx, a leading provider of ambulatory cardiac monitoring technologies and custom data solutions.
Ajax Health II, the latest medical device venture from serial healthcare entrepreneur Duke Rohlen, announced today that it has raised more than $85 million, which will be used to strategically operate and expand innovative medical device companies. HealthQuest Capital led the funding, with participation from Aisling Capital and Polaris Partners.
HealthQuest Capital, a growth capital firm investing in companies that optimize value in healthcare, today announced the close of HealthQuest Partners III, L.P. at $440 million, oversubscribed and closed at the hard cap. Fund III will be invested in commercial-stage companies delivering innovation across all sectors of the healthcare industry to improve patient outcomes, enhance efficiency and reduce costs.
Restoration Robotics (NASDAQ: HAIR), a global leader in robotic hair restoration, and Venus Concept, a privately-held global aesthetic technology leader, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
HealthQuest portfolio company Avedro, Inc. (Nasdaq: AVDR), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share, for total gross proceeds of $70.0 million.
Venus Concept announces the launch of its latest device, Venus Heal, which is now cleared in the U.S. to treat soft tissue injuries and conditions. Venus Heal is intended to relieve pain, improve blood circulation, and increase range of motion through the relief of muscle spasm.
Trice Medical announced that it is acquiring S.E.GWAY Orthopaedics (SegWAY), a leader in solutions for minimally invasive orthopedic procedures. SegWAY is best known for its Endoscopic Carpal Tunnel Release (ECTR), a device that supports minimally invasive carpal tunnel surgeries.
An article published in Arthroscopy: The Journal of Arthroscopic & Related Surgery further supports the benefits of HealthQuest portfolio company Trice’s Needle Arthroscopy. The results show Needle Arthroscopy is less costly and produces the same outcomes when compared to MRI.
HealthQuest has made an equity investment in Etairos Health. Etairos an in-home senior care company providing non-skilled and skilled care primarily to the senior population. Etairos acquires selected home care agencies that fit well with its care philosophy and business model, integrates and then expands them, allowing for the creation of a leading regional home care provider.
Castle Biosciences, a skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the appointment of G. Bradley Cole to its Board of Directors.
Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease
Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update
Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.
CareMetx, a technology-enabled hub services provider for pharmaceutical and biotechnology manufacturers, today announced they have acquired VirMedica, the leader in e-access technology solutions designed to streamline patient access to life-enhancing therapies.
HealthQuest participated in a $120M Series B financing into Ajax Health, a platform company focused on investing in and accelerating innovative medical technologies that address significant unmet clinical needs.
HealthQuest Capital portfolio company Avedro, today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations.
HealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors. Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants. HealthQuest was joined in this investment by Arboretum Ventures and select insiders.
HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft. NeoGraft is an industry leader in the area of hair restoration technologies. Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.
HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software. HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.
Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.